Business Context and Reporting Period
This Form 8-K is filed by Silverback Therapeutics, Inc. (SBTX), an emerging growth company, reporting a material event on May 2, 2022. The filing addresses the termination of a material definitive agreement regarding office space in Seattle, Washington.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is a termination fee obligation of $28,330 payable to the sublandlord, Delta Dental of Washington.
Material Changes
- Agreement Termination: The Company terminated a sublease agreement for approximately 9,188 square feet at 400 Fairview Avenue North, Seattle, originally dated July 1, 2021.
- Effective Date: The termination is effective as of July 31, 2022.
- Financial Impact: The Company is obligated to pay a one-time termination fee of $28,330.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general risks beyond the specific event of the lease termination. The document notes that the Company is an emerging growth company.
Investor Verification Checklist
- Verify the impact of the $28,330 termination fee on the Company's current cash position.
- Confirm the Company's plans for its remaining office space or relocation following the July 31, 2022, effective date.
- Review the original July 2, 2021, Form 8-K (Item 1.01) referenced in this filing for full details of the sublease terms.